Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Glaukos Corporation

GKOSNYSEEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 20, 2026Accepted Nov 20, 2026, 7:23 PM ESTFiling CIK 1644557Accession 0001193125-26-470661
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-11-18
Issuer
GLAUKOS Corp
Issuer CIK
0001192448
Trading symbol
GKOS
Rule 10b5-1 indication
Checked

Reporting owner 1

Name
Burns Thomas William
Reporting owner CIK
0001644557
Relationship
Director · Officer
Officer title
CHAIRMAN & CEO
Address
C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656

Non-derivative transactions

Non-derivative transactions · 15 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-11-18M · Form 4180,000A45.71245,060[F1]D
Common Stock2026-11-18S · Form 4[F2]40,450D232.61[F3]204,610[F1]D
Common Stock2026-11-18S · Form 4[F2]19,288D233.78[F4]185,322[F1]D
Common Stock2026-11-18S · Form 4[F2]25,558D234.74[F5]159,764[F1]D
Common Stock2026-11-18S · Form 4[F2]4,285D235.46[F6]155,479[F1]D
Common Stock2026-11-18S · Form 4[F2]15,689D237.29[F7]139,790[F1]D
Common Stock2026-11-18S · Form 4[F2]21,601D237.99[F8]118,189[F1]D
Common Stock2026-11-18S · Form 4[F2]10,096D239.27[F9]108,093[F1]D
Common Stock2026-11-18S · Form 4[F2]10,942D240.06[F10]97,151[F1]D
Common Stock2026-11-18S · Form 4[F2]5,421D241.14[F11]91,730[F1]D
Common Stock2026-11-18S · Form 4[F2]3,390D242.46[F12]88,340[F1]D
Common Stock2026-11-18S · Form 4[F2]6,919D243.02[F13]81,421[F1]D
Common Stock2026-11-18S · Form 4[F2]15,040D244.18[F14]66,381[F1]D
Common Stock2026-11-18S · Form 4[F2]1,087D245.31[F15]65,294[F1]D
Common Stock2026-11-18S · Form 4[F2]234D245.90[F16]65,060[F1]D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct
S · Form 4
Sale on the market or privately

Non-derivative holdings

Non-derivative holdings · 5 reported rows
SecurityAmount ownedOwnershipNature of ownership
Common Stock1,141,593IThrough the Burns Family Trust
Common Stock238,107IThrough the Burns Annuity Trust
Common Stock120,000IThrough the Burns Charitable Remainder Trust
Common Stock100,000IThrough the Thomas W. Burns Irrevocable Trust
Common Stock100,000IThrough the Janet M. Burns Irrevocable Trust
Table key
I
Indirect

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to Buy)45.712026-11-18M · Form 4180,000[F17]D0[F18]2027-03-15Common Stock180,0000D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
D
Direct

Footnotes

F1
Includes 48,673 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15
F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2026 with respect to options that expire on March 15, 2027.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14
F3
This transaction was executed in multiple trades at prices ranging from $232.17 to $233.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F4
This transaction was executed in multiple trades at prices ranging from $233.22 to $234.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F5
This transaction was executed in multiple trades at prices ranging from $234.23 to $235.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F6
This transaction was executed in multiple trades at prices ranging from $235.24 to $235.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F7
This transaction was executed in multiple trades at prices ranging from $236.60 to $237.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F8
This transaction was executed in multiple trades at prices ranging from $237.61 to $238.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F9
This transaction was executed in multiple trades at prices ranging from $238.64 to 239.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F10
This transaction was executed in multiple trades at prices ranging from $239.66 to $240.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F11
This transaction was executed in multiple trades at prices ranging from $240.68 to $241.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F12
This transaction was executed in multiple trades at prices ranging from $241.70 to $242.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F13
This transaction was executed in multiple trades at prices ranging from $242.72 to $243.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F14
This transaction was executed in multiple trades at prices ranging from $243.74 to $244.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F15
This transaction was executed in multiple trades at prices ranging from $244.76 to $245.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F16
This transaction was executed in multiple trades at prices ranging from $245.81 to $246.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
F17
The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2026 with respect to options that expire on March 15, 2027.↩ 1
F18
These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.↩ 1

Signature 1

Signed
Diana Scherer, Attorney-in-Fact
Date
2026-11-20

Company context

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding GLAUKOS CorpNov 16, 2026
  2. Regulation FD DisclosureNov 6, 2026
  3. 10-Q filingOct 28, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureOct 28, 2026
  5. 144 filingSep 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.